CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial…
- More than 70 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; enrollment complete and regulatory submissions planned for late 2022- -Initiated and began dosing patients in the pivotal trial of…